Detalhe da pesquisa
1.
Comparison of prognostic impact of atezolizumab plus bevacizumab versus lenvatinib in patients with intermediate-stage hepatocellular carcinoma.
Liver Int
; 44(1): 113-124, 2024 01.
Artigo
Inglês
| MEDLINE | ID: mdl-37789669
2.
Comparative analysis of the therapeutic outcomes of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma patients aged 80 years and older: Multicenter study.
Hepatol Res
; 54(4): 382-391, 2024 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-37983642
3.
Nutritional Status Is Associated with Prognosis in Patients with Advanced Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab.
Oncology
; 101(4): 270-282, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-36455517
4.
Lenvatinib as Second-Line Treatment after Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma: Clinical Results Show Importance of Hepatic Reserve Function.
Oncology
; 101(10): 624-633, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-37307798
5.
Comparison between Atezolizumab Plus Bevacizumab and Lenvatinib for Hepatocellular Carcinoma in Patients with Child-Pugh Class B in Real-World Clinical Settings.
Oncology
; 101(9): 542-552, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-37552968
6.
Association of proton pump inhibitor and antibiotic use with the clinical outcomes of hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: A multicenter analysis.
Hepatol Res
; 53(8): 737-748, 2023 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-37020416
7.
Geriatric nutritional risk index as an easy-to-use assessment tool for nutritional status in hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
Hepatol Res
; 53(10): 1031-1042, 2023 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-37306040
8.
Impact of first-line systemic therapy with atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
J Gastroenterol Hepatol
; 38(8): 1389-1397, 2023 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-37231943
9.
Simple Scoring System for Predicting TACE Unsuitable among Intermediate-Stage Hepatocellular Carcinoma Patients in the Multiple Systemic Treatment Era.
Oncology
; 100(2): 65-73, 2022.
Artigo
Inglês
| MEDLINE | ID: mdl-34844247
10.
Clinical Predictor of Urinary Protein as Adverse Event Associated with Atezolizumab plus Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma.
Oncology
; 100(12): 645-654, 2022.
Artigo
Inglês
| MEDLINE | ID: mdl-36103846
11.
Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysis.
Hepatol Res
; 52(5): 462-470, 2022 May.
Artigo
Inglês
| MEDLINE | ID: mdl-35080087
12.
Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC-B stage patients classified as beyond up to seven criteria - Multicenter analysis.
Hepatol Res
; 52(3): 308-316, 2022 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-34799975
13.
Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child-Pugh class A or B liver function in real-world clinical practice.
Hepatol Res
; 52(9): 773-783, 2022 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-35633504
14.
Impact of Early Lenvatinib Administration on Survival in Patients with Intermediate-Stage Hepatocellular Carcinoma: A Multicenter, Inverse Probability Weighting Analysis.
Oncology
; 99(8): 518-527, 2021.
Artigo
Inglês
| MEDLINE | ID: mdl-33906189
15.
Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib.
Liver Int
; 41(12): 2997-3008, 2021 12.
Artigo
Inglês
| MEDLINE | ID: mdl-34250737
16.
Therapeutic efficacy of lenvatinib as third-line treatment after regorafenib for unresectable hepatocellular carcinoma progression.
Hepatol Res
; 51(8): 880-889, 2021 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-33837620
17.
Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weighting.
J Gastroenterol Hepatol
; 36(7): 1812-1819, 2021 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-33171524
18.
Neutrophil-to-lymphocyte ratio is associated with survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib.
Liver Int
; 40(4): 968-976, 2020 04.
Artigo
Inglês
| MEDLINE | ID: mdl-32064740
19.
Histopathological analysis of autoimmune hepatitis with "acute" presentation: Differentiation from drug-induced liver injury.
Hepatol Res
; 50(9): 1047-1061, 2020 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-32515851
20.
Strategy for advanced hepatocellular carcinoma based on liver function and portal vein tumor thrombosis.
Hepatol Res
; 50(12): 1375-1385, 2020 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-32924266